Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Purpose. To assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis. Design. Multicenter, prospective case series. Methods. Thirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/560632 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556228179394560 |
|---|---|
| author | Carmen García-De-Vicuña Manuel Díaz-Llopis David Salom Rosa Bou Jesus Díaz-Cascajosa Miguel Cordero-Coma Gabriela Ortega Norberto Ortego-Centeno Marta Suarez-De-Figueroa Juan Cruz-Martínez Alex Fonollosa Ricardo Blanco Ángel María García-Aparicio Jose M. Benítez-Del-Castillo Jordi Antón |
| author_facet | Carmen García-De-Vicuña Manuel Díaz-Llopis David Salom Rosa Bou Jesus Díaz-Cascajosa Miguel Cordero-Coma Gabriela Ortega Norberto Ortego-Centeno Marta Suarez-De-Figueroa Juan Cruz-Martínez Alex Fonollosa Ricardo Blanco Ángel María García-Aparicio Jose M. Benítez-Del-Castillo Jordi Antón |
| author_sort | Carmen García-De-Vicuña |
| collection | DOAJ |
| description | Purpose. To assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis. Design. Multicenter, prospective case series. Methods. Thirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled. Patients aged 13–17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4–12 years received 24 mg/m2 body surface. Results. Inflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P<0.001). The mean (SD) macular thickness at baseline was 304.54 (125.03) μ and at the end of follow-up was 230.87 (31.12) μ (P<0.014). Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P<0.001). The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P<0.001). No significant side effects requiring discontinuation of therapy were observed. Conclusion. Adalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement. |
| format | Article |
| id | doaj-art-e3add3ee7c864cc999d596589de896e7 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e3add3ee7c864cc999d596589de896e72025-02-03T05:45:59ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/560632560632Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic ArthritisCarmen García-De-Vicuña0Manuel Díaz-Llopis1David Salom2Rosa Bou3Jesus Díaz-Cascajosa4Miguel Cordero-Coma5Gabriela Ortega6Norberto Ortego-Centeno7Marta Suarez-De-Figueroa8Juan Cruz-Martínez9Alex Fonollosa10Ricardo Blanco11Ángel María García-Aparicio12Jose M. Benítez-Del-Castillo13Jordi Antón14Ophthalmology Department, Hospital Sant Joan de Déu, Universidad de Barcelona, Passeig Sant Joan de Déu 2, Esplugues de Llobregat, 08950 Barcelona, SpainService of Ophthalmology, Hospital Universitari i Politècnic La Fe, and Facultad de Medicina, Universidad de Valencia, Valencia, SpainService of Ophthalmology, Hospital Universitari i Politècnic La Fe, and Facultad de Medicina, Universidad de Valencia, Valencia, SpainUnit of Pediatric Rheumatology, Pediatrics Department, Hospital Sant Joan de Déu, Universidad de Barcelona, Esplugues del Llobregat, Barcelona, SpainOphthalmology Department, Hospital Sant Joan de Déu, Universidad de Barcelona, Passeig Sant Joan de Déu 2, Esplugues de Llobregat, 08950 Barcelona, SpainService of Ophthalmology, Hospital de León, León, SpainLaboratory of Ocular Immunology and Uveitis, Instituto Nacional de Rehabilitación, Calzada Mexico-Xochimilco, Mexico, DF, MexicoService of Internal Medicine, Hospital San Cecilio, Granada, SpainService of Ophthalmology, Hospital Ramón y Cajal, Madrid, SpainService of Rheumatology, Hospital de Pontevedra, Pontevedra, SpainService of Ophthalmology, Hospital de Cruces, Bilbao, SpainService of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, SpainService of Rheumatology, Hospital Virgen de la Salud, Toledo, SpainService of Ophthalmology, Hospital Clínico San Carlos, Madrid, SpainUnit of Pediatric Rheumatology, Pediatrics Department, Hospital Sant Joan de Déu, Universidad de Barcelona, Esplugues del Llobregat, Barcelona, SpainPurpose. To assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis. Design. Multicenter, prospective case series. Methods. Thirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled. Patients aged 13–17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4–12 years received 24 mg/m2 body surface. Results. Inflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P<0.001). The mean (SD) macular thickness at baseline was 304.54 (125.03) μ and at the end of follow-up was 230.87 (31.12) μ (P<0.014). Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P<0.001). The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P<0.001). No significant side effects requiring discontinuation of therapy were observed. Conclusion. Adalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement.http://dx.doi.org/10.1155/2013/560632 |
| spellingShingle | Carmen García-De-Vicuña Manuel Díaz-Llopis David Salom Rosa Bou Jesus Díaz-Cascajosa Miguel Cordero-Coma Gabriela Ortega Norberto Ortego-Centeno Marta Suarez-De-Figueroa Juan Cruz-Martínez Alex Fonollosa Ricardo Blanco Ángel María García-Aparicio Jose M. Benítez-Del-Castillo Jordi Antón Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis Mediators of Inflammation |
| title | Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis |
| title_full | Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis |
| title_fullStr | Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis |
| title_full_unstemmed | Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis |
| title_short | Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis |
| title_sort | usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis |
| url | http://dx.doi.org/10.1155/2013/560632 |
| work_keys_str_mv | AT carmengarciadevicuna usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT manueldiazllopis usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT davidsalom usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT rosabou usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT jesusdiazcascajosa usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT miguelcorderocoma usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT gabrielaortega usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT norbertoortegocenteno usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT martasuarezdefigueroa usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT juancruzmartinez usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT alexfonollosa usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT ricardoblanco usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT angelmariagarciaaparicio usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT josembenitezdelcastillo usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis AT jordianton usefulnessofadalimumabinthetreatmentofrefractoryuveitisassociatedwithjuvenileidiopathicarthritis |